Conquering the meningococcus, FEMS Microbiol Rev, vol.31, pp.3-14, 2007. ,
Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage, J Prev Med Hyg, vol.56, pp.116-120, 2015. ,
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease, Microbiol Mol Biol Rev, vol.77, pp.234-252, 2013. ,
Meningococcal disease, N Engl J Med, vol.344, pp.1378-1388, 2001. ,
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis, Lancet ii, pp.355-357, 1983. ,
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis, Vaccine, vol.27, pp.3-12, 2009. ,
Immunologic response of man to group B meningococcal polysaccharide vaccines, J Infect Dis, vol.126, pp.514-521, 1972. ,
Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116, Abstracts of the Thirteenth International Pathogenic Neisseria Conference, 2002. ,
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein, Infect Immun, vol.72, pp.2088-2100, 2004. ,
Functional significance of factor H binding to Neisseria meningitidis, J Immunol, vol.176, pp.7566-7575, 2006. ,
A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups, Pediatr Infect Dis J, vol.32, pp.1096-1101, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02089119
Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic, Epidemiol Mikrobiol Imunol, vol.63, pp.103-106, 2014. ,
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis, J Infect Dis, vol.200, pp.379-389, 2009. ,
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, Lancet Infect Dis, vol.13, issue.13, pp.70006-70015, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02093031
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease, Vaccine, vol.28, pp.6086-6093, 2010. ,
Trumenba: a serogroup B meningococcal vaccine, Med Lett Drugs Ther, vol.57, pp.5-6, 2015. ,
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults, Vaccine, vol.31, pp.1569-1575, 2013. ,
A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents, Pediatr Infect Dis J, vol.32, pp.364-371, 2013. ,
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial, Lancet Infect Dis, vol.12, pp.70087-70094, 2001. ,
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial, Vaccine, vol.30, pp.6163-6174, 2012. ,
Meningococcal surrogates of protection-serum bactericidal antibody activity, Vaccine, vol.23, pp.2222-2227, 2005. ,
The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B fHBP Expression on NmB Isolates ® Disease, Hum Vaccin Immunother, vol.11, pp.5-13, 2015. ,
Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains, Pediatr Infect Dis J, vol.36, pp.216-223, 2017. ,
Meningococcal serogroup B vaccines: estimating breadth of coverage, Hum Vaccin Immunother, vol.13, pp.255-265, 2017. ,
Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086, J Biol Chem, vol.284, pp.8738-8746, 2009. ,
LP2086 and MLST distribution in epidemiologically relevant strains of serogroup B Neisseria meningitidis, p P137, Abstracts of the Sixteenth International Pathogenic Neisseria Conference. National Institute of Public Health, 2008. ,
Changes in Neisseria meningitidis disease epidemiology in the United States, Clin Infect Dis, vol.50, pp.184-191, 1998. ,
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States, Vaccine, vol.29, pp.4739-4744, 2011. ,
Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain, JAMA, vol.281, pp.1493-1497, 1999. ,
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance, J Immunol, vol.177, pp.501-510, 2006. ,
Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease, J Infect Dis, vol.190, pp.1488-1497, 2004. ,
Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage, Vaccine, vol.28, pp.7667-7675, 2010. ,
Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis, Vaccine, vol.27, pp.5755-5759, 2009. ,
Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined, Proc Natl Acad Sci U S A, vol.113, pp.2714-2719, 2016. ,
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease, Vaccine, vol.27, issue.2, pp.112-116, 2009. ,
Serum bactericidal antibody assays-the role of complement in infection and immunity, Vaccine, vol.33, pp.4414-4421, 2015. ,
The (alpha2¡8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum, Infect Immun, vol.66, pp.5939-5947, 1998. ,
Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis, Genome Res, vol.13, pp.391-398, 2003. ,
Resistance of Neisseria meningitidis to human serum depends on T and B cell stimulating protein B, Infect Immun, vol.83, pp.3134-3148, 2015. ,
Bactericidal activity of serums from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France, Vaccine, vol.35, pp.1530-1537, 2017. ,
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide, Vaccine, vol.27, pp.3417-3421, 2009. ,
Correction of light-scattering errors in spectrophotometric protein determinations, Biopolymers, vol.10, pp.1243-1251, 1971. ,
A simplification of the protein assay method of Lowry et al. which is more generally applicable, Anal Biochem, vol.83, pp.346-356, 1977. ,
Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level, Proc Natl Acad Sci U S A, vol.102, pp.15477-15482, 2005. ,
Protein structure change studied by hydrogendeuterium exchange, functional labeling, and mass spectrometry, 2003. ,
, Proc Natl Acad Sci U S A, vol.100, pp.7057-7062
Dynamics of cAPK type IIbeta activation revealed by enhanced amide H/2H exchange mass spectrometry (DXMS), J Mol Biol, vol.327, pp.234-235, 2003. ,
Rapid refinement of crystallographic protein construct definition employing enhanced hydrogen-deuterium exchange MS, 2004. ,
, Proc Natl Acad Sci U S A, vol.101, pp.751-756
High resolution, high-throughput amide deuterium exchange-mass spectrometry (DXMS) determination of protein binding site structure and dynamics: utility in pharmaceutical design, J Cell Biochem Suppl, vol.37, pp.89-98, 2001. ,
Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC, J Mol Biol, vol.425, pp.3429-3445, 2013. ,
Serogroup B and C serum bactericidal assays, Methods Mol Med, vol.66, pp.289-304, 2001. ,
, Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines, World Health Organization, 1999.